ASMB Assembly Biosciences, Inc. gains 21% Dec 7, 2017

Assembly Biosciences, Inc., a biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein, a polyfunctional viral protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under cGMP conditions, and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead drug candidate from the platform is AB-M101, is in development for the treatment of C. difficile- infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in Carmel, Indiana. http://www.priceseries.com/trade/ASMB-Assembly-Biosciences-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2017111620171207.html